Key points are not available for this paper at this time.
PURPOSE: Prostate-specific antigen progression (PSA-P) is an indicator of progression in hormone-sensitive (HS) and castration-resistant (CR) prostate cancer (PC). We evaluated different definitions of PSA-P as predictors of overall survival (OS). PATIENTS AND METHODS: A total of 1,078 patients with HSPC who were on hormones (Southwest Oncology Group SWOG trial 9346 S9346) and 597 patients with CRPC who were treated with chemotherapy (SWOG trial 9916 S9916) were eligible for this analysis. PSA-P definitions tested included the following: PSA Working Group, Prostate Cancer Working Group (PCWG 2008), and other definitions. A time-varying approach analyzed associations between PSA-P at any time and OS. A landmark analysis examined the relationship between PSA-P status at 7 months for S9346, or 3 months for S9916, and subsequent OS. RESULTS: In the time-varying analysis, both working groups definitions were strongly associated with OS (P or = 25% greater than the nadir and an absolute increase of at least 2 or 5 ng/mL, predicts OS in HSPC and CRPC and may be a suitable end point for phase II studies in these settings.
Hussain et al. (Tue,) studied this question.